According to the study, if a mutation in the retinoblastoma gene is found in a prostate cancer patient’s tumor, compared to those without the mutation, the patient is more than three times more likely to die and approximately six and a half times more likely to experience a relapse following standard treatment procedures.
The researchers are now studying new ways to treat patients with retinoblastoma gene mutations; with the discovery of the mutation’s impact, at-risk patients can now be identified earlier and treated more aggressively.
In their research into which genes are most closely tied to prostate cancer survival and relapse rates, the scientists found that the retinoblastoma gene is the only one that has such a significant effect on fatality, though two other genetic mutations can impact post-treatment relapse rates. Additionally, another mutation was found to indicate a positive response to immunotherapy and, in some cases, could be effectively treated with an existing breast cancer drug.
More articles about health IT:
Catasys will use AI, human interaction to address loneliness epidemic
Amazon voice assistant for children allegedly records, stores conversations
DirectTrust reports 49% increase in HIE for Q1
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
